References
- Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/anhtithrombotics: for and against? Clin. Chem. Lab. Med.49(5), 755–757 (2011).
- Holford NHG. New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better? Br. J. Clin. Pharmacol.48, 9–13 (1999).
- Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rovaroxaban: their suitability and limitations. Ther. Drug Monit.32(6), 673–679 (2010).
- Bereznicki LRE, Peterson GM. New antighrombotics for atrial fibrillation. Cardiovasc. Ther.28(5), 278–386 (2010).
- Ott I. Inhibitors of the initiation of coagulation. Br. J. Clin. Pharmacol.72(4), 547–552 (2011).
- Wajima T, Isbister GK, Duffull SB. A comprehensive model for the humoral coagulation network in humans. Clin. Pharmacol. Ther.86(3), 290–298 (2009).
- Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am. J. Hematol.85(3), 185–187 (2010).
- Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med.349(11), 1019–1026 (2003).
- Kurnik D, Loebstein HH, Gak E, Almog S. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics10(12), 1955–1965 (2009).
- Harenberg J, Wehling M. Future anticoagulant therapy. Cardiovasc. Ther.29(5), 291–300 (2011).
- Huo MH. New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better? Thromb. Haemost.106(1), 45–57 (2011).
- Mueck W, Eriksson BI, Bauer KA et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet.47(3), 203–216 (2008).
- Mueck W, Borris LC, Dahl OE et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb. Haemost.100(3), 453–461 (2008).
- Hamberg AK, Dahl ML, Barban M et al. A PK–PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin. Pharmacol. Ther.81(4), 529–538 (2007).
- Lane S, Al-Zubiedi S, Hatch E et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br. J. Clin. Pharmacol.73(1), 66–76 (2012).
- Hamberg AK, Wadelius M, Lindh JD et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1 and age. Clin. Pharmacol. Ther.87(6), 727–734 (2010).
- Troconiz I, Tillmann C, Liesenfeld KH, Schäfer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement. J. Clin. Pharmacol.47(3), 371–382 (2007).
- Akimoto K, Klinkhardt U, Zeiher A, Niethammer M, Harder S. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic–pharmacodynamic relationship of coagulation parameters. J. Clin. Pharmacol.51(6), 805–818 (2011).
- Bååthe S, Hamrén B, Karlsson MO et al. Population pharmacokinetics of melagatran, the active form of the direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy. Clin. Pharmacokinet.45(8), 803–819 (2006).
- Eastham RD, Slade RR. Bleeding, clotting and transfusion. Clinical Haematology (7th Edition). Butterworth Heinemann, Oxford, UK, 131–216 (1992).